Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Cash from Financing Activities: 2013-2024

Historic Cash from Financing Activities for Astria Therapeutics (ATXS) over the last 12 years, with Dec 2024 value amounting to $157.2 million.

  • Astria Therapeutics' Cash from Financing Activities rose 1026.78% to $3.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was $25.6 million, marking a year-over-year decrease of 42.16%. This contributed to the annual value of $157.2 million for FY2024, which is 77.83% up from last year.
  • Astria Therapeutics' Cash from Financing Activities amounted to $157.2 million in FY2024, which was up 77.83% from $88.4 million recorded in FY2023.
  • Astria Therapeutics' 5-year Cash from Financing Activities high stood at $157.2 million for FY2024, and its period low was $40.9 million during FY2020.
  • Moreover, its 3-year median value for Cash from Financing Activities was $144.7 million (2022), whereas its average is $130.1 million.
  • As far as peak fluctuations go, Astria Therapeutics' Cash from Financing Activities spiked by 155.22% in 2021, and later crashed by 38.92% in 2023.
  • Over the past 5 years, Astria Therapeutics' Cash from Financing Activities (Yearly) stood at $40.9 million in 2020, then skyrocketed by 155.22% to $104.3 million in 2021, then skyrocketed by 38.78% to $144.7 million in 2022, then plummeted by 38.92% to $88.4 million in 2023, then spiked by 77.83% to $157.2 million in 2024.